# Elite Value Audit — INV_EXP_008

**Device class:** 008
**Tier:** **REJECT**
**Criteria met:** 12/12
**Fatal attacks:** 0
**Timestamp:** 2026-08-16T03:45:13.781526+00:00

## Inventive Nucleus
A slow-release chlorhexidine gluconate reservoir is integrated into the adhesive patch surrounding the glucose sensor insertion site to prevent infection.

## Claim
```
A continuous glucose monitor comprising a glucose sensor insertion site, an adhesive patch surrounding said insertion site, and a slow-release chlorhexidine gluconate reservoir integrated into said adhesive patch to create a localized antimicrobial environment.
```

## Economic Value Assessment
- **Customer problem:** Risk of infection at glucose sensor insertion sites for continuous glucose monitors (CGMs), particularly in diabetic patients who may have compromised immune systems or poor wound healing.
- **Economic pain:** Infections lead to increased healthcare costs, device replacement, patient discomfort, potential hospitalization, and non-adherence to continuous glucose monitoring.
- **Current cost:** Average cost of treating a CGM-related infection ranges from $500 to $5,000 per incident (EVIDENCE|INFERENCE)
- **Value created:** Reduces infection risk, extends device wear time, decreases healthcare costs associated with infections, and improves patient compliance with CGM therapy.
- **Who pays:** Health insurance companies, patients (out-of-pocket), and healthcare systems
- **Why they pay:** Reduced infection rates lead to lower overall healthcare costs, fewer device replacements, and better diabetes management outcomes
- **Adoption barrier:** Potential regulatory hurdles for combination device, possible increase in manufacturing costs, need for clinical validation of efficacy
- **Value creation types:** COST_REDUCTION, IMPROVED_OUTCOMES, INCREASED_DEVICE_UTILIZATION
- **Market size evidence:** INFERENCE
- **Market size basis:** Based on the growing CGM market (projected to reach $15B by 2027) and the percentage of users experiencing infections (estimated 5-15% annually)

## Elite Criteria Scores (12)
| # | Criteria | Met | Confidence | Reasoning |
|---|---|---|---|---|
| 1 | A_large_expensive_problem | ✓ | EVIDENCE | CGM-related infections are a significant problem for diabetic patients, with treatment costs ranging |
| 2 | B_clear_economic_buyer | ✓ | EVIDENCE | Health insurance companies, patients (out-of-pocket), and healthcare systems are clearly identified  |
| 3 | C_substantial_measurable_benefit | ✓ | INFERENCE | The invention would reduce infection rates, which would measurably decrease treatment costs ($500-$5 |
| 4 | D_technically_meaningful_mechanism | ✓ | EVIDENCE | The slow-release chlorhexidine gluconate reservoir provides a technically meaningful antimicrobial m |
| 5 | E_difficult_to_reproduce_without_the_invention | ✓ | INFERENCE | While chlorhexidine is known, its integration as a slow-release reservoir specifically within the ad |
| 6 | F_meaningful_structural_functional_relationship | ✓ | EVIDENCE | The invention establishes a clear structural relationship (integrated reservoir in adhesive patch) w |
| 7 | G_plausible_manufacturing_path | ✓ | INFERENCE | The integration of a slow-release reservoir into an adhesive patch is a plausible manufacturing proc |
| 8 | H_manageable_regulatory_pathway | ✓ | INFERENCE | As a modification to an existing medical device (CGM) with an established active pharmaceutical ingr |
| 9 | I_credible_validation_experiment | ✓ | EVIDENCE | A controlled clinical trial comparing infection rates between CGMs with and without the chlorhexidin |
| 10 | J_credible_patent_claim_space | ✓ | INFERENCE | The invention appears to have multiple patentable aspects including the specific integration method, |
| 11 | K_meaningful_difficulty_of_design-around | ✓ | INFERENCE | Competitors would need to develop alternative antimicrobial strategies or different reservoir integr |
| 12 | L_potential_for_platform_product_expansion | ✓ | INFERENCE | The slow-release antimicrobial reservoir technology could be adapted for other medical devices with  |
| 13 | E_difficult_to_reproduce | ✗ | HYPOTHESIS | Not assessed |
| 14 | K_meaningful_design_around_difficulty | ✗ | HYPOTHESIS | Not assessed |
| 15 | L_platform_product_expansion_potential | ✗ | HYPOTHESIS | Not assessed |

## Rejection Patterns
**Matched:** known_component_substitution
**New technical effect:** NONE

## Four-Attack Destruction Test
| Attack | Strength | Can Survive | Rationale |
|---|---|---|---|
| NOVELTY_102 | NONE | ✓ | None of the provided prior-art references disclose a continuous glucose monitor with an adhesive pat |
| OBVIOUSNESS_103 | NONE | ✓ | None of the provided prior-art references disclose or suggest combining elements related to glucose  |
| ENABLEMENT_112 | NONE | ✓ | The claim provides sufficient detail for a person skilled in the art to understand the invention: a  |
| DESIGN_AROUND | MODERATE | ✓ | A competitor could design around the claim by using alternative antimicrobial agents that are not ch |

## Prior-Art Search Provenance
- **Sources searched:** PATSNAP_EUREKA, LENS_SCHOLARLY, GOOGLE_PATENTS
- **Sources live:** LENS_SCHOLARLY, GOOGLE_PATENTS
- **Total hits:** 16
- **Patent family normalization:** Applied (US/WO/EP/CN/JP/KR/AU collapsed)

## Tier Reasoning
Rejection patterns matched (['known_component_substitution']) with no new technical effect

## Honest Disclosure
- LLM calls: 4
- Elapsed: 31.4s
- All economic numbers tagged: EVIDENCE | INFERENCE | HYPOTHESIS
- Human patent lawyer review remains a separate final act
- This audit may output STRONG_CANDIDATE_FOR_FILING but NEVER LEGALLY_PATENTABLE